End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite rules of ther­a­peu­tic DNA

In a CD­MO in­dus­try flush with cash from Covid-19, the rich keep get­ting rich­er — but that doesn’t mean the top dogs aren’t look­ing for op­por­tu­ni­ties …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.